bymuratdeniz ADMA Biologics, Inc. (NASDAQ:ADMA) specializes in developing and commercializing plasma-derived products for infectious diseases. However, ADMA’s market mostly focuses on immune-compromised patients. The company’s IP portfolio centers around three FDA-approved medications: Asceniv, Bivigam, and Nabi-HB. ADMA’s revenue streams primarily come from their FDA-approved products, with additional income from patented immunotechnology and contract development and manufacturing organization [CDMO] se ...